$OVID
Ovid Therapeutics Inc.

2023 Q1 Form 10-K Financial Statement

#000162828023007648 Filed on March 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $66.16K $46.28K $1.503M
YoY Change -95.42% -99.28%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.344M $6.663M $32.43M
YoY Change -15.72% -19.72% -12.82%
% of Gross Profit
Research & Development $6.615M $5.556M $24.62M
YoY Change -15.55% -69.3% -47.55%
% of Gross Profit
Depreciation & Amortization $144.7K $185.0K $512.5K
YoY Change 95.98% 116.17%
% of Gross Profit
Operating Expenses $14.96M $12.22M $57.05M
YoY Change -15.55% -53.72% -32.22%
Operating Profit -$14.89M -$55.55M
YoY Change -8.45% -144.72%
Interest Expense $1.136M $1.068M $1.879M
YoY Change 468.05%
% of Operating Profit
Other Income/Expense, Net $1.536M -$400.0K $1.379M
YoY Change 634.8% -3118.45%
Pretax Income -$13.36M -$11.50M -$54.17M
YoY Change -16.83% -56.26% -143.63%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$13.36M -$11.50M -$54.17M
YoY Change -17.08% -55.75% -144.1%
Net Earnings / Revenue -20187.74% -24859.1% -3604.66%
Basic Earnings Per Share -$0.19 -$0.77
Diluted Earnings Per Share -$0.19 -$0.16 -$0.77
COMMON SHARES
Basic Shares Outstanding 70.49M shares 70.47M shares 70.42M shares
Diluted Shares Outstanding 70.49M shares 70.42M shares

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $117.7M $129.0M $129.0M
YoY Change -29.38% -31.31% -31.31%
Cash & Equivalents $63.05M $44.87M $42.01M
Short-Term Investments $54.67M $84.13M $84.13M
Other Short-Term Assets $1.799M $2.379M $2.379M
YoY Change -25.03% -11.88% -11.88%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $119.5M $131.4M $131.4M
YoY Change -29.73% -31.03% -31.03%
LONG-TERM ASSETS
Property, Plant & Equipment $1.053M $1.148M $16.07M
YoY Change 308.4% 372.89% 7935.32%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $5.982M $5.100M $5.623M
YoY Change 273.9% 218.75% 251.41%
Other Assets $212.5K $261.2K $1.970M
YoY Change -12.92% 59.17% -1.51%
Total Long-Term Assets $23.85M $23.89M $23.89M
YoY Change 13.51% 487.49% 497.13%
TOTAL ASSETS
Total Short-Term Assets $119.5M $131.4M $131.4M
Total Long-Term Assets $23.85M $23.89M $23.89M
Total Assets $143.4M $155.3M $155.3M
YoY Change -24.98% -20.19% -20.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.831M $1.953M $1.953M
YoY Change -18.84% -72.6% -72.49%
Accrued Expenses $4.085M $4.505M $5.039M
YoY Change -48.75% -41.28% -34.56%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.721M $6.992M $6.992M
YoY Change -34.11% -52.75% -52.76%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $15.70M $16.00M $16.00M
YoY Change -1.27%
Total Long-Term Liabilities $15.70M $16.00M $16.00M
YoY Change -1.27%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.721M $6.992M $6.992M
Total Long-Term Liabilities $15.70M $16.00M $16.00M
Total Liabilities $22.42M $22.99M $22.99M
YoY Change -14.1% 55.38% 55.36%
SHAREHOLDERS EQUITY
Retained Earnings -$238.9M -$225.5M
YoY Change 27.44% 31.6%
Common Stock $70.49K $70.47K
YoY Change -99.98% -99.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $120.9M $132.3M $132.3M
YoY Change
Total Liabilities & Shareholders Equity $143.4M $155.3M $155.3M
YoY Change -24.98% -20.19% -20.17%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$13.36M -$11.50M -$54.17M
YoY Change -17.08% -55.75% -144.1%
Depreciation, Depletion And Amortization $144.7K $185.0K $512.5K
YoY Change 95.98% 116.17%
Cash From Operating Activities -$12.10M -$9.176M -$55.20M
YoY Change -39.8% -23.54% -146.54%
INVESTING ACTIVITIES
Capital Expenditures $13.56K $63.00K $1.224M
YoY Change -70.48% -131.5% 565.39%
Acquisitions
YoY Change
Other Investing Activities $30.24M -$4.107M -$86.46M
YoY Change -3124.24% 5304.03%
Cash From Investing Activities $30.23M -$4.170M -$87.88M
YoY Change -2908.94% 4069.51% 4725.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $66.99K -43.60K $180.7K
YoY Change 102.52% -143.6% -80.02%
NET CHANGE
Cash From Operating Activities -$12.10M -9.176M -$55.20M
Cash From Investing Activities $30.23M -4.170M -$87.88M
Cash From Financing Activities $66.99K -43.60K $180.7K
Net Change In Cash $18.20M -13.39M -$142.9M
YoY Change -186.12% 11.57% -221.44%
FREE CASH FLOW
Cash From Operating Activities -$12.10M -$9.176M -$55.20M
Capital Expenditures $13.56K $63.00K $1.224M
Free Cash Flow -$12.11M -$9.239M -$56.42M
YoY Change -39.87% -21.71% -147.65%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 ovid Available For Sale Securities Gross Realized Gain Loss Net1
AvailableForSaleSecuritiesGrossRealizedGainLossNet1
0 usd
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001636651
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-38085
CY2022 dei Entity Registrant Name
EntityRegistrantName
Ovid Therapeutics Inc.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-5270895
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
441 Ninth Avenue
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
14th Floor
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10001
CY2022 dei City Area Code
CityAreaCode
646
CY2022 dei Local Phone Number
LocalPhoneNumber
661-7661
CY2022 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2022 dei Trading Symbol
TradingSymbol
OVID
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
124900000 usd
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
70491510 shares
CY2022 dei Auditor Firm
AuditorFirmId
185
CY2022 dei Auditor Name
AuditorName
KPMG LLP
CY2022 dei Auditor Location
AuditorLocation
New York, New York
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44867846 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
187797532 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
84133565 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2379280 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2681597 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
131380691 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
190479129 usd
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
5622547 usd
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
1631992 usd
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
1930753 usd
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
1930753 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
14922669 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1147963 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
242757 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
261191 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
260126 usd
CY2022Q4 us-gaap Assets
Assets
155265814 usd
CY2021Q4 us-gaap Assets
Assets
194544757 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1952910 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7127046 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4504669 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7671275 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
533946 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6991525 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14798321 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
16001725 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd
CY2022Q4 us-gaap Liabilities
Liabilities
22993250 usd
CY2021Q4 us-gaap Liabilities
Liabilities
14798321 usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 ovid Preferred Stock Share Designated
PreferredStockShareDesignated
10000 shares
CY2021Q4 ovid Preferred Stock Share Designated
PreferredStockShareDesignated
10000 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1250 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1250 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1250 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1250 shares
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
1 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
1 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
70466885 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
70466885 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
70364912 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
70364912 shares
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
70467 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
70359 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
357770825 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
351033589 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-42187 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-225526542 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-171357513 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
132272564 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
179746436 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
155265814 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
194544757 usd
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1502748 usd
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
208382779 usd
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24618399 usd
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46939583 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
32432510 usd
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
37234104 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
57050909 usd
CY2021 us-gaap Operating Expenses
OperatingExpenses
84173687 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-55548161 usd
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
124209092 usd
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1379132 usd
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-45690 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-54169029 usd
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
124163402 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1328818 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-54169029 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
122834584 usd
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.77
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.78
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.77
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.76
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70424819 shares
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67479403 shares
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70424819 shares
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
68067992 shares
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-54169029 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
122834584 usd
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-42187 usd
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0 usd
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-54211216 usd
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
122834584 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
179746436 usd
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
180658 usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6556686 usd
CY2022 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
-42187 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-54169029 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
132272564 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
43631656 usd
CY2021 us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
7300000 usd
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
925739 usd
CY2021 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 usd
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5054457 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
122834584 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
179746436 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-54169029 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
122834584 usd
CY2022 ovid Non Cash Research And Development Expense
NonCashResearchAndDevelopmentExpense
0 usd
CY2021 ovid Non Cash Research And Development Expense
NonCashResearchAndDevelopmentExpense
7300000 usd
CY2022 ovid Noncash Consideration Received In Licensing Agreement Transaction
NoncashConsiderationReceivedInLicensingAgreementTransaction
945366 usd
CY2021 ovid Noncash Consideration Received In Licensing Agreement Transaction
NoncashConsiderationReceivedInLicensingAgreementTransaction
0 usd
CY2022 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-454811 usd
CY2021 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
0 usd
CY2022 ovid Interest Income And Accretion Of Discounts Short Term Investments
InterestIncomeAndAccretionOfDiscountsShortTermInvestments
-1211311 usd
CY2021 ovid Interest Income And Accretion Of Discounts Short Term Investments
InterestIncomeAndAccretionOfDiscountsShortTermInvestments
0 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
6556686 usd
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
5054457 usd
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
512505 usd
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
237079 usd
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
869100 usd
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
0 usd
CY2022 ovid Accretion Of Lease Liability
AccretionOfLeaseLiability
936927 usd
CY2021 ovid Accretion Of Lease Liability
AccretionOfLeaseLiability
0 usd
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-109292 usd
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-40503 usd
CY2022 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-5174136 usd
CY2021 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1702497 usd
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3166606 usd
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4361410 usd
CY2022 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0 usd
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-12382779 usd
CY2022 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
0 usd
CY2021 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-2432192 usd
CY2022 us-gaap Increase Decrease Due From Affiliates
IncreaseDecreaseDueFromAffiliates
0 usd
CY2021 us-gaap Increase Decrease Due From Affiliates
IncreaseDecreaseDueFromAffiliates
-141763 usd
CY2022 ovid Increase Decrease In Prepaid Expense Noncurrent
IncreaseDecreaseInPrepaidExpenseNoncurrent
0 usd
CY2021 ovid Increase Decrease In Prepaid Expense Noncurrent
IncreaseDecreaseInPrepaidExpenseNoncurrent
-477171 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-55227127 usd
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
118611673 usd
CY2022 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
172964441 usd
CY2021 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
0 usd
CY2022 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
90000000 usd
CY2021 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
0 usd
CY2022 us-gaap Payments To Acquire Longterm Investments
PaymentsToAcquireLongtermInvestments
2500000 usd
CY2021 us-gaap Payments To Acquire Longterm Investments
PaymentsToAcquireLongtermInvestments
1631992 usd
CY2022 ovid Payments For Proceeds From Issuance Of Short Term Note Receivable
PaymentsForProceedsFromIssuanceOfShortTermNoteReceivable
1000000 usd
CY2021 ovid Payments For Proceeds From Issuance Of Short Term Note Receivable
PaymentsForProceedsFromIssuanceOfShortTermNoteReceivable
0 usd
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1224379 usd
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
184008 usd
CY2022 us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
194397 usd
CY2021 us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
5400 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-87883217 usd
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1821400 usd
CY2022 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 usd
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
21314 usd
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
180658 usd
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
925396 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
180658 usd
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
904082 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-142929686 usd
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
117694355 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
189728285 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
72033930 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46798599 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
189728285 usd
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
15791769 usd
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
CY2022 ovid Conversion Of Short Term Note Receivable To Long Term Equity Investment
ConversionOfShortTermNoteReceivableToLongTermEquityInvestment
1000000 usd
CY2021 ovid Conversion Of Short Term Note Receivable To Long Term Equity Investment
ConversionOfShortTermNoteReceivableToLongTermEquityInvestment
0 usd
CY2022Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
129000000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
222500000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-225500000 usd
CY2022Q4 ovid Working Capital
WorkingCapital
124400000 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-55200000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-54200000 usd
CY2022 us-gaap Use Of Estimates
UseOfEstimates
Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates.
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2022Q4 us-gaap Equity Method Investments
EquityMethodInvestments
5100000 usd
CY2021Q4 us-gaap Equity Method Investments
EquityMethodInvestments
1600000 usd
CY2022 us-gaap Equity Method Investment Other Than Temporary Impairment
EquityMethodInvestmentOtherThanTemporaryImpairment
0 usd
CY2021 us-gaap Equity Method Investment Other Than Temporary Impairment
EquityMethodInvestmentOtherThanTemporaryImpairment
0 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
84100000 usd
CY2022 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
CY2022 ovid Defined Contribution Plan Name
DefinedContributionPlanName
401(k)-retirement plan
CY2022 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
339405 usd
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
438043 usd
CY2022 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
ReclassificationsCertain prior period amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations.
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
84175752 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
42187 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
84133565 usd
CY2022Q4 ovid Cash Cash Equivalents And Available For Sale Debt Securities Amortized Cost
CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost
129043599 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
42187 usd
CY2022Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
129001411 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
0 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0 usd
CY2021Q4 ovid Cash Cash Equivalents And Available For Sale Debt Securities Amortized Cost
CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost
187797532 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0 usd
CY2021Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
187797532 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0 investment
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0 investment
CY2021 ovid Available For Sale Securities Gross Realized Gain Loss Net1
AvailableForSaleSecuritiesGrossRealizedGainLossNet1
0 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
581381 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
262208 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1147963 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
242757 usd
CY2022 us-gaap Depreciation
Depreciation
319173 usd
CY2021 us-gaap Depreciation
Depreciation
76871 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
222100 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
164092 usd
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
193333 usd
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
160208 usd
CY2022Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P10Y
CY2022Q1 us-gaap Land Subject To Ground Leases
LandSubjectToGroundLeases
19000 sqft
CY2022 us-gaap Payments For Rent
PaymentsForRent
2300000 usd
CY2022Q1 ovid Lessee Operating Lease Rent Payments Commencement Following This Period
LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod
P10M
CY2022Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P10Y
CY2022Q1 ovid Lessee Operating Lease Free Rent Period
LesseeOperatingLeaseFreeRentPeriod
P2M
CY2022Q4 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P10Y
CY2022Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2022Q4 ovid Lease Incremental Borrowing Rate
LeaseIncrementalBorrowingRate
0.0702
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
14922669 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
533946 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
16001725 usd
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
1806028 usd
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
0 usd
CY2022 us-gaap Short Term Lease Cost
ShortTermLeaseCost
0 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1672886 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2316303 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2316303 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2316303 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
2316303 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
12347235 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
23285333 usd
CY2022 ovid Common Stock Number Of Votes For Each Share
CommonStockNumberOfVotesForEachShare
1 vote
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3233802 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3764666 usd
CY2022Q4 ovid Accrued Research And Development
AccruedResearchAndDevelopment
395247 usd
CY2021Q4 ovid Accrued Research And Development
AccruedResearchAndDevelopment
1795190 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
682664 usd
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1564955 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
192956 usd
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
546464 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4504669 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7671275 usd
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022 us-gaap Dividends
Dividends
0 usd
CY2022 us-gaap Dividends
Dividends
0 usd
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6556686 usd
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5054457 usd
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6556686 usd
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5054457 usd
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10403420 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.26
CY2022 us-gaap Equity Securities Fv Ni Unrealized Loss
EquitySecuritiesFvNiUnrealizedLoss
500000 usd
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M2D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
652438 usd
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
5395658 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
6.45
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P6Y1M17D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
445599 usd
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2045913 shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.53
CY2021 ovid Share Based Compensation By Share Based Payment Award Options Granted Contractual Life
ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife
P9Y5M19D
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
288525 shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.36
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1384050 shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.08
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10776758 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.97
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y25D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2389890 usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
6188200 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
5.98
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P4Y7M17D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
1531907 usd
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4575641 shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.89
CY2022 ovid Share Based Compensation By Share Based Payment Award Options Granted Contractual Life
ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife
P9Y3M3D
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
25518 shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.91
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
2365643 shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.56
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12961238 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.13
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M1D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
62158 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
6742890 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
5.05
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P6Y2M12D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
61214 usd
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
12100000 usd
CY2022 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M3D
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
10400000 usd
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M9D
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
10400000 usd
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-26500000 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
55472573 usd
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
49086998 usd
CY2022Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
6332176 usd
CY2021Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
7121484 usd
CY2022Q4 ovid Deferred Tax Assets Capitalized Research And Development Costs
DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
4246071 usd
CY2021Q4 ovid Deferred Tax Assets Capitalized Research And Development Costs
DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
0 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4384751 usd
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4663578 usd
CY2022Q4 ovid Deferred Tax Assets Tax Deferred Expense Lease Liability
DeferredTaxAssetsTaxDeferredExpenseLeaseLiability
3544624 usd
CY2021Q4 ovid Deferred Tax Assets Tax Deferred Expense Lease Liability
DeferredTaxAssetsTaxDeferredExpenseLeaseLiability
0 usd
CY2022Q4 ovid Deferred Tax Assets Deferred Expense Research And Development Tax Credits
DeferredTaxAssetsDeferredExpenseResearchAndDevelopmentTaxCredits
3046253 usd
CY2021Q4 ovid Deferred Tax Assets Deferred Expense Research And Development Tax Credits
DeferredTaxAssetsDeferredExpenseResearchAndDevelopmentTaxCredits
2422331 usd
CY2022Q4 ovid Deferred Tax Liabilities Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxLiabilitiesTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
0 usd
CY2021Q4 ovid Deferred Tax Liabilities Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxLiabilitiesTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
28243 usd
CY2022Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
0 usd
CY2021Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
87672 usd
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
241096 usd
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
51920 usd
CY2022Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
3198857 usd
CY2021Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
0 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
97494 usd
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
0 usd
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
73683989 usd
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
63301900 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
73683989 usd
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
63301900 usd
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 usd
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 usd
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.0027
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0105
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.0126
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.0053
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.1850
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2139
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.0128
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.0105
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0225
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0093
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0107
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 usd
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 usd
CY2021Q4 ovid License Agreement Milestone Payments
LicenseAgreementMilestonePayments
203000000 usd
CY2022Q3 ovid Research And Development Arrangement Research Plan And Budget Expected Costs
ResearchAndDevelopmentArrangementResearchPlanAndBudgetExpectedCosts
3000000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-54169029 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
122834584 usd
CY2022 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
0 usd
CY2021 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
2997344 usd
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-54169029 usd
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
119837240 usd
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-54169029 usd
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
119837240 usd
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70424819 shares
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67479403 shares
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70424819 shares
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
68067992 shares
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.77
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.78
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.77
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.76

Files In Submission

Name View Source Status
0001628280-23-007648-index-headers.html Edgar Link pending
0001628280-23-007648-index.html Edgar Link pending
0001628280-23-007648.txt Edgar Link pending
0001628280-23-007648-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
ovid-20221231.htm Edgar Link pending
ovid-20221231.xsd Edgar Link pending
ovid-20221231_g1.gif Edgar Link pending
ovid-20221231_g2.jpg Edgar Link pending
ovid-20221231_g3.jpg Edgar Link pending
ovid-20221231_g4.jpg Edgar Link pending
ovid2022exhibit231.htm Edgar Link pending
ovid2022exhibit311.htm Edgar Link pending
ovid2022exhibit312.htm Edgar Link pending
ovid2022exhibit321.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ovid-20221231_cal.xml Edgar Link unprocessable
ovid-20221231_def.xml Edgar Link unprocessable
ovid-20221231_lab.xml Edgar Link unprocessable
ovid-20221231_pre.xml Edgar Link unprocessable
ovid-20221231_htm.xml Edgar Link completed
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending